Curis(US:CRIS)2026-03-19 21:32Financial Data and Key Metrics Changes - Curis reported a net income of $19.4 million or $1.23 per share for Q4 2025, compared to a net loss of $9.6 million or $1.25 per share for Q4 2024, primarily due to a $27.2 million one-time non-cash gain from the sale of Erivedge [10] - For the year ended December 31, 2025, Curis reported a net loss of $7.6 million or $0.58 per share, an improvement from a net loss of $43.4 million or $6.88 per share for the same period in 2024 [10] - Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, and for the year, they were $28.3 million compared to $38.6 million in 2024 [11] - General and administrative expenses also decreased to $2.9 million in Q4 2025 from $3.4 million in Q4 2024, totaling $14 million for the year compared to $16.8 million in 2024 [11] Business Line Data and Key Metrics Changes - The Take Aim Lymphoma study is progressing well, focusing on primary CNS lymphoma, with expectations for accelerated submissions in the U.S. and Europe [4][9] - Curis is exploring the potential of emavusertib to change treatment paradigms in CLL, aiming to improve upon the current standard of care with BTK inhibitors [5][6] Market Data and Key Metrics Changes - Enrollment in the Take Aim Lymphoma study is on track, with expectations for full enrollment within 12-18 months, potentially leading to data availability in 2027 [23] - The company is prioritizing NHL studies over AML, with a focus on registrational approval for PCNSL [15][16] Company Strategy and Development Direction - Curis aims to change the treatment paradigm for CLL by combining emavusertib with BTK inhibitors, targeting deeper responses and potential complete remission [6][7] - The company is actively engaging with key opinion leaders to expand studies into additional NHL subtypes, indicating a strategic focus on broadening its clinical research [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and the potential for significant advancements in 2026, particularly in the registrational study for PCNSL and the proof of concept study for CLL [9] - The management acknowledged the challenges in patient enrollment for PCNSL but remains confident in the study's trajectory [23] Other Important Information - Curis' cash and cash equivalents as of December 31, 2025, along with expected proceeds from financing, should support operations into the second half of 2027 [12] Q&A Session Summary Question: How is Curis prioritizing trial progress between pivotal PCNSL versus CLL and AML? - Management indicated that resources are being prioritized towards NHL, particularly PCNSL, while CLL is also a focus but at a smaller scale currently [14][15] Question: Can you provide updates on enrollment for PCNSL? - Management confirmed that enrollment is on track, with expectations for full enrollment within 12-18 months [23] Question: Should revenue modeling for 2026 reflect no meaningful revenue? - Management confirmed that there will be no meaningful revenue for 2026, as revenue effectively ended in November 2025 [29] Question: What kind of data should be expected at ASH 2026 for CLL? - Management stated that they hope to present meaningful data at ASH, focusing on the execution of the study and patient enrollment [38][40]